Displaying drugs 1801 - 1825 of 1930 in total
Rolofylline
Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.
Investigational
Clenoliximab
Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …
Interferon Kappa
Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding...
Investigational
Matched Description: … This gene encoding for this interferon is expressed in human epidermal keratinocytes. ... has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino ... Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
N,N-dimethylarginine
Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a...
Experimental
Matched Description: … It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human ... ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sifalimumab
Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to...
Investigational
Matched Description: … Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. ... other autoimmune disorders, and may be associated with disease activity. ... interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Omburtamab
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours.[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous...
Investigational
Matched Description: … CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours ... [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are …
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and ... an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and ... Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients …
Tabelecleucel
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers....
Investigational
Matched Description: … [A253292,A253297,L43557]
In October 2022, the EMA's Committee for Medicinal Products for Human Use ... Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers ... (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and pediatric …
OAV201
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
Matched Description: … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human ... It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation …
Icotinib
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the...
Experimental
Investigational
Matched Description: … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ( ... TKI)
Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
Umifenovir
Umifenovir is an indole-based, hydrophobic, dual-acting direct antiviral/host-targeting agent used for the treatment and prophylaxis of influenza and other respiratory infections. It has been in use in Russia for approximately 25 years and in China since 2006. Its invention is credited to a collaboration between Russian scientists from several research...
Investigational
Matched Description: … non-enveloped RNA and DNA viruses, including _Flavivirus_,[A191388] Zika virus,[A191391] foot-and-mouth ... prophylaxis of influenza and other respiratory infections. ... C viruses, chikungunya virus, reovirus, Hantaan virus, and coxsackie virus B5. …
XL228
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
Matched Description: … anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and ... Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis …
Sufugolix
Investigational
Mometasone
Mometasone is a corticosteroid not currently used in medical products. Mometasone furoate however, is still in use.
Experimental
Matched Categories: … indacaterol and mometasone ... indacaterol, glycopyrronium bromide and mometasone …
Pralnacasan
Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).
Investigational
Urelumab
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in...
Investigational
Matched Description: … Urelumab is a fully human antibody that targets CD137. ... Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. ... Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
LV-SMENP Vaccine
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
MDX-1379
MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Investigational
Velusetrag
Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research...
Investigational
Matched Description: … Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. …
Tandutinib
MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations...
Investigational
Matched Description: … Food and Drug Administration. Phase I/II trials are underway. ... type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and ... Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in …
ADU-S100
ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable...
Investigational
Matched Description: … ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression ... of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Tomaralimab
Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
Investigational
Matched Description: … under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Tegoprubart
Investigational
Displaying drugs 1801 - 1825 of 1930 in total